Abstract
X-linked adrenoleukodystrophy (X-ALD) is characterized by progressive neurological disability and primary adrenocortical insufficiency as a consequence of mutations in the ABCD1 gene that encodes a peroxisomal ATP binding cassette protein (Moseret al 2000a; Kempet al 2001) with a minimum incidence of 1:17,000 (Bezman et al. 2001). More than 400 different mutations have been identified (Kemp et al 2001). It is associated with the accumulation of saturated very long chain fatty acids, principally hexacosanoic (C26:0) and tetracosanoic acid (C24:0). High levels of these fatty acids are present in plasma (Moser et al 1999a). The neurologic manifestations show a wide range of severity. The childhood cerebral form (CCER) often leads to total disability and death by 10 years of age. Adrenomyeloneuropathy (AMN) presents as a paraparesis in young adults and progresses slowly (Powers et al 2000). Members of a family often have widely varying phenotypes. It is not possible to predict future course in asymptomatic young boys on the basis of mutation analysis, concentrations of VLCFA in plasma or cultured skin fibroblasts or phenotype in family members. The adrenal insufficiency in X-ALD can be treated successfully with steroid replacement therapy but apparently this does not alter the progression of the neurologic disease (Moser et al 2000a). Bone marrow transplantation (BMT) has been found to be of long-term benefit in boys and adolescents with cerebral involvement (Shapiro et al. 2000), but carries a high risk and is most effective when cerebral involvement is still mild.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aubourg, P., Adamsbaum, C, Lavallard-Rousseau, M. C, Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C, Lemaitre, A., Boureau, F., Wolf, C, 1993, A two-year trial of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N. Engl. J. Med. 329: 745–752.
Auestad, N., Halter, R., Hall, R. T., Blatter, M., Bogle, M. L., Burks, W., Erickson, J. R., Fitzgerald, K. M., Dobson, V., Innis, S. M., Singer, L. T., Montalto, M. B., Jacobs, J. R., Qiu, W., and Bomstein, M. H., 2001, Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 108: 372–381.
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., and Moser, H. W., 2001, Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann. Neurol. 49: 512–517.
Bezman, L. and Moser, H. W., 1998, Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am. J. Med. Genet. 76: 415–419.
Bourre, J. M., Daudu, O., and Baumann, N., 1976, Nervonic acid biosynthesis by erucyl-CoA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-CoAs (mono and poly-unsaturated). Biochim. Biophys. Acta 424: 1–7.
Cox, R. D., 1972, Regression models and life tables. J. Royal Statistics Soc. 34: 187–220.
Efron, B. and Feldman, D., 1991, Compliance as an explanatory variable in clinical trials. J. Am. Stat. Assoc . 86 9-26 .
Eichler, F. S., Barker, P. B., Cox, C, Edwin, D., Ulug, A. M., Moser, H. W., and Raymond, G. V., 2002, Proton MR spectroscopic imaging predicts lesion progression on MRI in X- linked adrenoleukodystrophy. Neurology 58: 901–907.
Ho, J. K., Moser, H., Kishimoto, Y., and Hamilton, J. A., 1995, Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Invest. 96: 1455–1463.
Hunneman, D. H. and Hanefeld, F., 1987, Diagnose von peroxisomalen Erkrankungen - Erfahrungen mit einer empfindlichen masenfragmentographischen Bestimung der sehr langkettigen Fettsauren und der Phytansaure im plasma. Monatsschr. Kinderheilkd. 136: 529.
Kaplan, P. W., Tusa, R. J., Shankroff, J., Heller, J., and Moser, H. W., 1993, Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann. Neurol. 34: 169–174.
Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J., and Moser, H. W., 2001, ABCD1 mutations and the X- linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum. Mutat . IS : 499-515 .
Korenke, G. C, Hunneman, D. H., Kohler, J., Stockier, S., Landmark, K., and Hanefeld, F., 1995, Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X- chromosomal adrenoleukodystrophy/ adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur. J. Pediatr. 154: 64–70.
Lee, W. E., Wei, L. J., and Amato, D. A., 1992, Cox-type regression for large numbers of small groups of correlated failure time observations. In Survival Analysis: State of the Art (J. P. Klein and P. K. Goel, eds.), Kluwer Academic Publisher, Dordrecht, The Netherlands, pp. 237–247.
Loes, D. J., Hite, S., Moser, H., Stillman, A. E., Shapiro, E., Lockman, L., Latchaw, R. E., and Krivit, W., 1994, Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am. J. Neuroradiol. 15: 1761–1766.
Moser, A. B., Jones, D. S., Raymond, G. V., and Moser, H. W., 1999, Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem. Res. 24: 187–197.
Moser, A. B., Kreiter, N., Bezman, L., Lu, S., Raymond, G. V., Naidu, S., and Moser, H. W., 1999, Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann. Neurol 45: 100–110.
Moser, H. W., Aubourg, P., Cornblath, D., Borel, J., Wu, Y.-W., Bergin, A., and Naidu, S., 1991, Therapy for X-linked adrenoleukodystrophy. In Treatment of Genetic Disease (R. J. Desnick, ed.), Churchill Livingstone, New York, pp. 111–129.
Moser, H. W. and Borel, J., 1995, Dietary management of X-linked adrenoleukodystrophy. Annu. Rev. Nutr . 15 379-397 .
Moser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., and Lu, S. E., 2000, X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 31 227-239 .
Moser, H. W., Smith, K. D., Watkins, P. A., Powers, J., and Moser, A. B., 2000, X-linked adrenoleukodystrophy. In The Metabolic and Molecular Bases of Inherited Disease (C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, eds.), McGraw Hill, New York, pp. 3257–3301.
Murphy, E. J., 2002, Lorenzo’s Oil, adrenoleukodystrophy, and the blood brain barrier.J. Neurochem.81: S100.
O’Connor, D. L., Hall, R., Adamkin, D., Auestad, N., Castillo, M., Connor, W. E., Connor, S. L., Fitzgerald, K., Groh-Wargo, S., Hartmann, E. E., Jacobs, J., Janowsky, J., Lucas, A., Margeson, D., Mena, P., Neuringer, M., Nesin, M., Singer, L., Stephenson, T., Szabo, J., and Zemon, V., 2001, Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics 108: 359–371.
Odone, A. and Odone, M., 1989, Lorenzo’s oil. J. Pediatr. Neurosci. 5: 55.
Poulos, A., Gibson, R., Sharp, P., Beckman, K., and Grattan-Smith, P., 1994, Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo’s oil. Ann. Neurol. 36: 741–746.
Powers, J. M., DeCiero, D. P., Ito, M., Moser, A. B., and Moser, H. W., 2000, Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy.. J. Neuropathol. Exp. Neurol . 59 89-102 .
Rasmussen, M., Moser, A. B., Borel, J., Khangoora, S., and Moser, H. W., 1994, Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo’s oil). Neurochem. Res. 19: 1073–1082.
Rizzo, W. B., Leshner, R. T., Odone, A., Craft, D. A., Jennings, S. S., Jaitly, R., 1990, X- linked adrenoleukodystrophy: Biochemical and clinical efficacy of dietary erucic acid therapy . In Adrenoleukodystrophy and Other Peroxisomal Disorders (G. Uziel, R. J. A. Wanders, and M. E. Cappa, eds.), Excerpta Medica, Amsterdam, pp. 149–162.
Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., Jennings, S. S., Davis, S., Jaitly, R., and Sgro, J. A., 1989, Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39: 1415–1422.
Shapiro, E., Krivit, W., Lockman, L., Jambaque, I., Peters, C, Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., Ziegler, R., Crittenden, M., Ris, D., Berg, B., Cox, C, Moser, H., Fischer, A., and Aubourg, P., 2000, Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356 713–718.
Uziel, G., Bertini, E., Bardelli, P., Rimoldi, M, and Gambetti, M., 1991, Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev. Neurosci. 13: 274–279.
van Geel, B. M., Assies, J., Haverkort, E. B., Koelman, J. H., Verbeeten, B. Jr., Wanders, R. J., and Barth, P. G., 1999, Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil.” J. Neurol Neurosurg. Psychiatry 67: 290–299.
Whitcomb, R. W., Linehan, W. M., and Knazek, R. A., 1988, Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J. Clin. Invest. 81: 185–188.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this paper
Cite this paper
Moser, H.W. et al. (2003). Evaluation of the Preventive Effect of Glyceryl Trioleate-Trierucate (“Lorenzo’s Oil”) Therapy in X-Linked Adrenoleukodystrophy: Results of Two Concurrent Trials. In: Roels, F., Baes, M., De Bie, S. (eds) Peroxisomal Disorders and Regulation of Genes. Advances in Experimental Medicine and Biology, vol 544. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9072-3_47
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9072-3_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4782-8
Online ISBN: 978-1-4419-9072-3
eBook Packages: Springer Book Archive